NCT06806345 Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause
| NCT ID | NCT06806345 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Cairo University |
| Condition | Insulin Resistance Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-01-28 |
| Primary Completion | 2025-03-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 40 participants in total. It began in 2025-01-28 with a primary completion date of 2025-03-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: In postmenopausal females, Insulin resistance is commonly encountered in clinical setting. Hyperbaric oxygen therapy have been proposed effective in lowering blood glucose level and improving function. Identification of clinical examination variables as predictors to blood glucose levels and dysfunction would offer therapists the chance to undertake clinical decisions and consequently improve treatment efficiency. Objectives: This Predictive validity, diagnostic study conduct to examine the effect of hyperbaric oxygen therapy on insulin resistance in postmenopausal women.
Eligibility Criteria
Inclusion Criteria: * A)Inclusion Criteria * All females were clinically diagnosed with Postmenopausal Insulin resistance. * Their ages were ranged from 55-65 years old. * Their BMI was 30-34.9 kg/m². * All patients should had controlled blood glucose levels by oral hypoglycemic drugs. * All patients should had cardiac Ejection Fraction \>or =50%. * Their Chest X-ray reported normal. * Their Ear ,nose , thorax will be clinically evaluated by a specialized ENT physician to ensure fitting for hyperbaric chamber * Voluntary acceptance of participation in the study . B)Exclusion Criteria: Participants will be excluded if they have : * Chronic obstructive pulmonary disease. * Cardiac pacemakers. * Epileptic fits. * Physically disable . * Any disorder that lead to ulcers other than diabetes such as ahistory of chronic peripheral arterial disease. Exclusion Criteria: \-
Contact & Investigator
Siham mohamed fahmy Head of Hyperbaric oxygen therapy unit, Assistant professor
✉ Fahmysiham@gmail.com📞 01033380185
Frequently Asked Questions
Who can join the NCT06806345 clinical trial?
This trial is open to female participants only, aged 55 Years or older, up to 65 Years, studying Insulin Resistance Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06806345 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06806345 currently recruiting?
Yes, NCT06806345 is actively recruiting participants. Contact the research team at Fahmysiham@gmail.com for enrollment information.
Where is the NCT06806345 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06806345 clinical trial?
NCT06806345 is sponsored by Cairo University. The trial plans to enroll 40 participants.